Clinical Trial Update: Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating pembrolizumab in EGFR-mutant, tyrosine kinase inhibitor–naive advanced non-small cell lung cancer has completed; results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-07-14